Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
东曜药业有限公司 TOT BIOPHARM
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES
2022-10-27 08:00
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares
2022-06-02 08:00
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China
2021-12-02 08:00
TOT BIOPHARM Anounces 2021 Interim Results
2021-08-13 10:59
TOT BIOPHARM raises US$102 million in Series B Financing Round
2018-08-08 19:00
TOT BIOPHARM's 16,000L-capacity monoclonal antibodies production base put into operation
2018-06-21 10:40
1